Abbott Laboratories (NYSE:ABT) Holdings Decreased by Tiemann Investment Advisors LLC

Tiemann Investment Advisors LLC lessened its stake in Abbott Laboratories (NYSE:ABT) by 1.5% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 9,823 shares of the healthcare product maker’s stock after selling 150 shares during the period. Tiemann Investment Advisors LLC’s holdings in Abbott Laboratories were worth $1,111,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Impax Asset Management Group plc lifted its position in shares of Abbott Laboratories by 0.5% in the 3rd quarter. Impax Asset Management Group plc now owns 557,608 shares of the healthcare product maker’s stock valued at $63,573,000 after acquiring an additional 2,754 shares in the last quarter. Summit Global Investments raised its holdings in shares of Abbott Laboratories by 13.4% during the 3rd quarter. Summit Global Investments now owns 4,103 shares of the healthcare product maker’s stock valued at $468,000 after purchasing an additional 486 shares in the last quarter. CWA Asset Management Group LLC acquired a new position in Abbott Laboratories during the third quarter worth $1,044,000. United Bank raised its holdings in Abbott Laboratories by 1.8% during the third quarter. United Bank now owns 27,284 shares of the healthcare product maker’s stock valued at $3,111,000 after buying an additional 488 shares in the last quarter. Finally, Assetmark Inc. boosted its stake in shares of Abbott Laboratories by 11.4% during the 3rd quarter. Assetmark Inc. now owns 132,020 shares of the healthcare product maker’s stock worth $15,052,000 after acquiring an additional 13,523 shares in the last quarter. 75.18% of the stock is owned by institutional investors.

Abbott Laboratories Stock Up 1.6 %

Shares of Abbott Laboratories stock opened at $137.23 on Monday. The firm has a market cap of $238.00 billion, a PE ratio of 17.94, a P/E/G ratio of 2.52 and a beta of 0.70. Abbott Laboratories has a 52-week low of $99.71 and a 52-week high of $141.23. The business’s 50 day simple moving average is $125.35 and its 200 day simple moving average is $118.82. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.14 and a current ratio of 1.60.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Wednesday, January 22nd. The healthcare product maker reported $1.34 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.34. Abbott Laboratories had a net margin of 31.95% and a return on equity of 20.74%. The firm had revenue of $10.97 billion for the quarter, compared to analyst estimates of $11.03 billion. During the same period in the previous year, the business earned $1.19 EPS. The company’s revenue was up 7.2% compared to the same quarter last year. On average, analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, May 15th. Stockholders of record on Tuesday, April 15th will be issued a $0.59 dividend. This represents a $2.36 annualized dividend and a dividend yield of 1.72%. The ex-dividend date is Tuesday, April 15th. Abbott Laboratories’s payout ratio is presently 30.85%.

Wall Street Analyst Weigh In

ABT has been the topic of a number of recent analyst reports. Royal Bank of Canada reissued an “outperform” rating and issued a $135.00 price objective on shares of Abbott Laboratories in a research note on Tuesday, January 21st. Evercore ISI boosted their price objective on shares of Abbott Laboratories to $136.00 and gave the stock a “buy” rating in a research note on Thursday, January 2nd. Citigroup raised their target price on Abbott Laboratories from $135.00 to $160.00 and gave the company a “buy” rating in a report on Tuesday, March 4th. Barclays reissued an “overweight” rating and issued a $158.00 price objective (up from $149.00) on shares of Abbott Laboratories in a research report on Monday, January 27th. Finally, Stifel Nicolaus lifted their price objective on Abbott Laboratories from $130.00 to $135.00 and gave the company a “buy” rating in a report on Thursday, January 23rd. Four research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $137.19.

Insider Activity at Abbott Laboratories

In related news, EVP Andrea F. Wainer sold 949 shares of Abbott Laboratories stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $138.17, for a total transaction of $131,123.33. Following the completion of the transaction, the executive vice president now owns 74,381 shares in the company, valued at approximately $10,277,222.77. This trade represents a 1.26 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Eric Shroff sold 562 shares of the company’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $138.17, for a total value of $77,651.54. Following the completion of the sale, the senior vice president now owns 31,970 shares in the company, valued at $4,417,294.90. This represents a 1.73 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 116,449 shares of company stock valued at $15,463,316. 1.10% of the stock is owned by corporate insiders.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.